



**HAL**  
open science

## Guidelines for Perioperative Care for Liver Transplantation

Raffaele Brustia, Antoine Monsel, Stefano Skurzak, Eduardo Schiffer, François Martin Carrier, Damiano Patrono, Abdourahamane Kaba, Olivier Detry, Luiz Malbouisson, Wellington Andraus, et al.

► **To cite this version:**

Raffaele Brustia, Antoine Monsel, Stefano Skurzak, Eduardo Schiffer, François Martin Carrier, et al.. Guidelines for Perioperative Care for Liver Transplantation. Transplantation, 2021, Publish Ahead of Print, 10.1097/TP.0000000000003808 . hal-03240160

**HAL Id: hal-03240160**

**<https://hal.science/hal-03240160>**

Submitted on 28 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Transplantation Publish Ahead of Print**

**DOI: 10.1097/TP.0000000000003808**

**Guidelines for Perioperative Care for Liver Transplantation: Enhanced Recovery After Surgery (ERAS) Society Recommendations**

Raffaele Brustia,<sup>1</sup> Antoine Monsel,<sup>2</sup> Stefano Skurzak,<sup>3</sup> Eduardo Schiffer,<sup>4</sup> François Martin Carrier,<sup>5</sup> Damiano Patrono,<sup>6</sup> Abdourahamane Kaba,<sup>7</sup> Olivier Detry,<sup>8</sup> Luiz Malbouisson,<sup>9</sup> Wellington Andraus,<sup>10</sup> Franck Vandenbroucke-Menu,<sup>11</sup> Gianni Biancofiore,<sup>12</sup> Toshimi Kaido,<sup>13</sup> Philippe Compagnon,<sup>14</sup> Shinji Uemoto,<sup>13</sup> Gonzalo Rodriguez Laiz,<sup>15</sup> Marieke De Boer,<sup>16</sup> Susan Orloff,<sup>17</sup> Paulo Melgar,<sup>18</sup> Carlijn Buis,<sup>16</sup> Miriam Zeillemaker-Hoekstra,<sup>19</sup> Helen Usher,<sup>20</sup> Koen Reyntjen,<sup>21</sup> Emily Baird,<sup>22</sup> Nicolas Demartines,<sup>23</sup> Stephen Wigmore,<sup>24</sup> Olivier Scatton<sup>25</sup>

<sup>1</sup>Department of Hepatobiliary and Liver Transplantation Surgery, AP-HP, Hôpital de la Pitié-Salpêtrière, F-75013 Paris, France; Université de Picardie-Jules Verne, UR UPJV 7518 SSPC, F-80000, Amiens, France.

<sup>2</sup>Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France. - Sorbonne Université, INSERM, UMR-S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France. - Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.

<sup>3</sup>Department of Anesthesiology and Critical Care, A.O.U. Città della Salute e della Scienza di Torino Torino, Italy

<sup>4</sup>Division of Anesthesiology, Department of Anesthesiology, Clinical Pharmacology, Intensive Care and Emergency Medicine, Geneva, Switzerland.

<sup>5</sup>University of Montreal Hospital Research Center, Canada; Department of Anesthesiology and Department of Medicine, Division of Critical Care, University of Montreal Hospital Centre, Canada

<sup>6</sup>General Surgery 2U - Liver Transplant Unit, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, University of Torino, Corso Bramante 88-90, 10126, Torino, Italy.

<sup>7</sup>Department of Anaesthesiology (AMH, A-SJM, AK, JLJ), Service of Abdominal Surgery, CHU Liège, University of Liège, Domaine du Sart Tilman, Liège, Belgium

<sup>8</sup>Division of Abdominal Surgery and Transplantation, University of Liège Hospital (CHU ULiège), Liège, Belgium

<sup>9</sup>Anesthesiology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

<sup>10</sup>Digestive Organs Transplant Division, Gastroenterology Department, Sao Paulo University School of Medicine, Sao Paulo, Brazil

<sup>11</sup>HPB Surgery and Liver Transplantation Unit, CHUM St-Luc, University of Montreal, 1058 Saint-Denis, Montreal, QC, H2X 3J4, Canada

<sup>12</sup>Transplant Anesthesia and Critical Care Unit, University School of Medicine, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy

<sup>13</sup>Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

<sup>14</sup>Division of Transplantation, Department of Surgery, Geneva University Hospitals, Geneva, Switzerland

<sup>15</sup>Department of General & Digestive Surgery, ISABIAL, Hospital General Universitario de Alicante, Spain

<sup>16</sup>Section Hepato-Pancreatico-Biliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>17</sup>Oregon Health & Science University, Department of Surgery, Division of Abdominal Organ Transplantation, United States

<sup>18</sup>Department of Anesthesiology and Critical Care, Gastroenterology Department, Sao Paulo University School of Medicine, Sao Paulo, Brazil

<sup>19</sup>Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands

<sup>20</sup>Department of Anesthesiology and Critical Care, Edinburgh Transplant Centre, Royal Infirmary of Edinburgh, UK

<sup>21</sup>Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

<sup>22</sup>Oregon Health & Science University, Department of Anesthesiology and Critical Care, United States

<sup>23</sup>Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne UNIL, Rue du Bugnon 46, 1011, Lausanne, Switzerland

<sup>24</sup>Department of Clinical Surgery, University of Edinburgh and Edinburgh Transplant Centre, Royal Infirmary of Edinburgh, UK

<sup>25</sup>Department of Digestive, Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, AP-HP Pitié-Salpêtrière, Sorbonne Université, Centre de Recherche de Saint-Antoine (CRSA), INSERM, UMRS-938, Paris, France.

Correspondence: Professor Olivier Scatton Director, Liver Transplantation Surgical Program  
Liver Transplantation and Hepatology Department, Hôpital Pitié-Salpêtrière 47-83 Boulevard  
de l'Hôpital Paris 75013 Tel: + 33 (1) 42.17.56.52 Fax: + 33 (1) 42.17.56.17 E-mail:  
olivier.scatton@aphp.fr

**FINANCIAL SUPPORT** This study is part of a nongrant-funded PhD project on enhanced  
recovery after liver transplantation.

**CONFLICT OF INTEREST:** None.

#### **AUTHORS CONTRIBUTIONS**

RB performed the systematic review, planned the e-delphi consensus, wrote and edited the  
manuscript;

AM performed the systematic review, participated to the consensus, wrote 1 part of the  
manuscript and edited the manuscript;

SS performed the systematic review, participated to the consensus, wrote 1 part of the  
manuscript and edited the manuscript;

ES and DP performed the systematic review, participated to the consensus, revised critically  
and edited the manuscript;

SW and ND participated to the consensus, offered insights, revised critically and edited the  
manuscript.

All the remaining Authors participated to the consensus, revised critically and edited  
the manuscript.

OS moreover supervised the strategy and revised critically and edited the manuscript.

## **ABSTRACT**

### **BACKGROUND:**

Enhanced Recovery After Surgery (ERAS) is a multimodal, evidence-based, program of care developed to minimize the response to surgical stress, associated with reduced perioperative morbidity and hospital stay. This study presents the specific ERAS Society recommendations for liver transplantation (LT) based on the best available evidence and on expert consensus

### **METHODS:**

PubMed and ClinicalTrials.gov were searched in April 2019 for published and ongoing RCTs on LT in the last 15 years. Studies were selected by 5 independent reviewers, and were eligible if focusing on each validated ERAS items in the area of adult LT. An e-Delphi method was used with an extended interdisciplinary panel of experts to validate the final recommendations.

### **RESULTS:**

Forty-three articles were included in the systematic review. Consensus was reached among experts after the second round. Patients should be screened for malnutrition and treated whenever possible. Prophylactic nasogastric intubation and prophylactic abdominal drainage may be omitted, and early extubation should be considered. Early oral intake, mobilization and multimodal-balanced analgesia are recommended.

### **CONCLUSIONS:**

The current ERAS recommendations were elaborated based on the best available evidence and endorsed by the e-Delphi method. Nevertheless, prospective studies need to confirm the clinical use of the suggested protocol.

PROSPERO CRD4201913279

## **BACKGROUND**

Enhanced Recovery After Surgery (ERAS) is a multimodal, evidence-based, program of care developed to minimize the response to surgical stress.<sup>1,2</sup>

The concept is based on a multidisciplinary team working around the patient, to ensure the synergic application of 20 program elements throughout each phase of the patient's journey.<sup>2</sup>

The implementation of ERAS recommendations in major surgery domains including colorectal,<sup>3</sup> pancreatic<sup>4</sup> and liver<sup>5</sup> surgery is associated with an improved recovery with a reduction in postoperative complications and hospital length of stay but without an increase in readmission rates .<sup>6-8</sup>

Liver Transplantation (LT) is a life-saving treatment for end-stage liver disease (ESLD),<sup>9</sup> with 1 and 5 years survival of 83%-92% and 71%- 87%, respectively.<sup>10-13</sup> In spite of these positive survival results complications are common and frailty, preoperative comorbidities, surgical challenges and postoperative immunosuppression are responsible of 40%-92% all-confounded morbidity.<sup>10,14-18</sup>

Liver surgery and liver transplantation share many points in common and the same principles of enhanced recovery may apply for liver transplantation. Nevertheless, little evidence exists on the application of an ERAS program in LT, apart from 2 feasibility studies reporting on the effectiveness of such a program on the length of stay after LT.<sup>19,20</sup>

This study aims to develop the specific ERAS Society recommendations for liver transplantation based on the best available evidence and on expert consensus.

## **METHODS**

An international panel of liver transplant surgeons and anaesthesiologists from 12 international centers, including the steering committee (Liège-Belgium, Sao Paulo-Brazil, Montréal-Canada, Torino-Italy, Pisa-Italy, Kyoto-Japan, Groningen-Netherlands, Paris-France, Alicante-Spain, Genève-Switzerland, Portland-US, Edinburgh-UK) were invited to participate.

These guidelines were realized according to the Recommendations from the ERAS® Society for standards for the development of enhanced recovery after surgery<sup>21</sup> and the Appraisal of Guidelines, Research and Evaluation (AGREE) recommendations,<sup>22</sup> with LT surgeons, anaesthesiologists or LT hepatologists as target users.

### **Items analysed**

The ERAS Guidelines for Liver Surgery<sup>5</sup> were used as working basis to develop the present guidelines, including the list of examined items. Hence, given some particular aspects of LT, a preliminary draft including the list of items on which the guideline would focus on was submitted for approval to all the experts. These agreed to remove the Mechanical/Oral bowel preparation item, considered as irrelevant in LT context, and “prehabilitation”, “temporary portocaval shunt”, “early extubation”, “postoperative education” items were added. The final list included 22 items. According to the methodology used for the development of the previous ERAS guidelines on Liver Surgery<sup>5</sup>, 22 different search equations were realized, 1 for each keywords group defining a validated ERAS item (preadmission counselling, prehabilitation, fluid and carbohydrate loading, no prolonged fasting, no/selective bowel preparation, antibiotic prophylaxis, thromboprophylaxis, no premedication, short acting anaesthetic agents, temporary portocaval shunt, mid-thoracic epidural anaesthesia, no drains, avoidance of salt and water overload, maintenance of normothermia, no nasogastric tubes, prevention of nausea and vomiting, early extubation, early removal of catheter, early oral nutrition, early mobilisation, nonopioid oral analgesia, stimulation of gut motility, postoperative education, audit of compliance and outcomes).

### **Literature search and data extraction**

The coordinator centre (Pitié Salpêtrière, Paris, France) realized a digital search Medline through PubMed for published studies and ClinicalTrials.gov for ongoing trials, focusing on each validated ERAS items in the area of liver transplantation. Each single validated ERAS



item was defined by a group of specific keywords extracted from official ERAS guidelines and 1 pilot study on ERAS and LT.<sup>2,3,5,19,23,24</sup>

*Participants/population*

Human adult patients (18 years or older) undergoing LT, with a graft (whole or split) coming from a deceased (after brain or cardiac death) or living donor, no matter the indication for LT. Articles focusing on re-transplantation or combined LT (with kidney, hearth, lung, pancreas or intestine) were not considered because of different patterns of morbidity and mortality. Studies focusing on paediatric LT and experimental studies including animals were not considered for inclusion.

*Intervention(s), exposure(s)*

No restriction on the type of intervention tested were applied, provided that the target population is composed of patients undergoing LT. According to the ERAS protocol, interventions could be during the preoperative, intraoperative or postoperative period immediately after LT.

*Comparator(s)/control*

None

*Main outcome(s)*

Outcomes assessed: all primary outcomes reported in the result section were extracted with the related definition, and severity score when provided. Measures of effect were classed (e.g. clinical outcome, surgical outcome, mortality, morbidity, recovery outcome, patients reported outcomes<sup>25</sup>) as well as the direction of effect (in favour vs against).

*Setting*

No restriction on study location or settings were applied.

*Language*

We will consider articles reported in English, French, German, Italian or Portuguese. Studies

in other languages will be included only if the translation can be adequately obtained through Google translate.

### *Types of study included*

Were considered for inclusion prospective or retrospective studies (cohorts or registry), case control or randomized clinical trials (RCT). If relevant, reviews and meta-analyses were evaluated for inclusion. Case reports were excluded, as well as any study including less than 10 patients. Abstracts, letters to the editor or conference posters were not considered for inclusion because of the lack of complete methods and results description.

Manual cross-references among the included studies were searched, for relevant related citations. The searches were done from 15/04/2019 – to 28/04/2019. The results of the literature research were screened by 5 investigators (2 surgeons: RB, DP, 3 anaesthesiologists: AM, SS, ES) on the basis of title and abstract through an on-line support.<sup>26</sup> Doubtful inclusions were resolved through discussion. A standardized data collection form, specifically designed for the purpose of this study, was used by 3 investigators for data extraction from published articles or for ongoing trials at ClinicalTrials.gov. After selection and inclusion for qualitative analysis, each trial was scored for quality (Risk of Bias tool - Cochrane collaboration's tool,<sup>27</sup> Jadad score,<sup>28</sup> and GRADE<sup>29</sup>).

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement<sup>30</sup>: the protocol was registered on the International Prospective Register of Systematic Reviews<sup>31</sup> current May 2019 (PROSPERO CRD42019132798).

### **Recommendation drafting**

Based on the results of the literature search, a working group composed by 3 investigators (RB, AM, SS) prepared, for each item

- *The supporting text*: concise, focused on relevant publications to support the evidence of the recommendations. If necessary, a few additional publications could be cited to support and explain the supporting text but without providing an extensive review of the literature.
- *The recommendation*: was defined as a statement that contained a course of action such as a preventive or treatment activity. Recommendations should contain the verbs can/may (weak), should or shall (strong) depending on the recommendation grade. Recommendations were based not only on quality of evidence but also on the balance between desirable and undesirable effects and on the values and the preferences. The latter implies that, in some cases, strong recommendations may be reached from low-quality data and vice versa.<sup>29</sup>
- *The grade of evidence* based on the Oxford level of evidence<sup>32</sup> (ranging from 1 to 5) and GRADE quality of evidence<sup>29</sup> (“high”, “moderate”, “low” and “very low”). Shortly, the GRADE assessment approach provides a structured way to consider key factors that may increase or decrease confidence towards a synthesized body of evidence, and particularly on the quality of evidence in the body of literature supporting the evidence itself. The final analysis may be classified as high, moderate, low and very low depending on the importance of outcomes, risk of bias, heterogeneity, indirectness, imprecision and publication bias.<sup>21</sup>
- *The strength of recommendation* There was not necessarily a 1:1 relation between strength of the recommendation (strong/weak) and the quality of the evidence. The strength of recommendation should also take into account criteria such as consistency of study results, clinical relevance of endpoints (outcomes) and effect sizes, risk-benefit ratio, patient preferences, application to the relevant patient group, application to

healthcare setting, legal and economic considerations. Based on these criteria, upgrading or downgrading of grades of recommendation was allowed.<sup>33</sup>

### **Consensus process (Delphi)**

The strength of recommendation, quality of evidence and conclusions were assessed and agreed by a 3 round e-Delphi process. The Delphi technique is a structured research tool for building consensus within a panel of experts around a specific topic through multiple interactions with questionnaires.<sup>34–36</sup> We sought to compose a heterogeneous panel in order to bring a range of disciplinary viewpoints, mirroring the multidisciplinary management of LT across caregivers and the “core philosophy” of multimodal ERAS management. Experts in LT surgery, anesthesiology and critical care from 12 high-volume LT centers (Liège-Belgium, Sao Paulo-Brazil, Montréal-Canada, Torino-Italy, Pisa-Italy, Kyoto-Japan, Groningen-Netherlands, Paris-France, Alicante-Spain, Genève-Switzerland, Portland-US, Edinburgh-UK) were contacted by e-mail in November 2019 and invited to participate. There is no consensus on the sample size of participants required for a Delphi panel, but a minimum of 10 is considered acceptable.<sup>37</sup> Here we invited 27 experts in this phase.

We used the modified electronic Delphi design, where the ‘modified’ term refers to the use of systematic literature review and expert discussion to drive the first provisional checklist for the initial questionnaire round rather than open interview on a broad list of items.<sup>38,39</sup> Online Delphi studies are free of charge compared to paper-based Delphi or face-to-face meetings, and are particularly suitable when experts are scattered across countries.<sup>38</sup> We consequently predefined a 3-phase sequence of rounds with iterative feedback.<sup>40</sup> We solicited each expert up to 3 times after each round. Consensus was considered as reached if more than 80% of the experts rated the item within the highest region of the scale (7, 8 or 9 on the 9-point Likert scale).<sup>41</sup> Once consensus was reached for a given item, that item was removed and no longer proposed in the following round. Experts were given 2 weeks to respond to each round,

followed by 2 reminders to complete the questionnaire that were sent out after 7 and 14 days. A 2-week interval between rounds was used to summarize the data and develop the next questionnaire.

We did not plan an external revision of final recommendations, but an updating procedure will be proposed every 5 years.

## **RESULTS**

Among the 2685 references identified by the PubMed search, 43 were included. From the search on Clinicaltrials.gov, we identified 62 references and included 6 ongoing trials. The selection process is detailed in Figure 1, and the complete list of trials can be found in Supplementary\_material\_study\_list <http://links.lww.com/TP/C225> .

### **Characteristics of the included trials**

Among the included studies, 40 (93%) were from single centers, including a median of 105 (38.5-171.5) patients. The design was prospective in 25 (55.8%) of included studies, with 12 (27.9%) randomized. The experimental intervention was nonpharmacological, pharmacological and combined in 23 (53.5%), 19 (44.2%) and 1 (2.3%) of studies.

The indication of LT was detailed in 32 studies (74.4%), with the use of deceased donor graft, LDLT or both reported in 15 (34.9%), 9 (20.9%) and 3 (7.0%) of cases, respectively. The reported level of evidence according to the GRADE<sup>29</sup> was rated as high in 3 (7%), moderate in 16 (37.2%), low in 16 (37.2%) and very low in 7 (16.3%) of the 43 published references. More details in Table 1.

### **e-Delphi process results.**

Among the 27 experts invited, 21 (81%) replied from 12 international LT centers reporting a median volume of 70 (40-112.5) LT per year: n=7 centres reported low-intermediate volume (<75 LT/year<sup>42-44</sup>), and 5 high-volume (>75-100 LT/year<sup>42-44</sup>).

The round-1 questionnaire was sent in November 2019, and data collection was completed

within 3 months, in February 2020. Figure 2 gives further information on the e-Delphi panel, with an average  $15.7 \pm 7.86$  years of experience. After round 1, consensus was reached for 16/22 criteria, with 2 of them requiring minor rewording. Changes were made to the wording used to describe the criteria, prompted by the panel's suggestions, and after round 2, consensus was reached for all the remaining criteria. The figure 3 shows the trend of consensus rating for each criterion across the last 2 rounds.

Within the Table 2 are summarized the ERAS recommendations for each item and the respective level of evidence, and in the supplementary\_material\_supporting\_text <http://links.lww.com/TP/C225> is exposed the rationale for each recommendation.

## CONCLUSIONS

This systematic review highlights how current available evidence on enhanced recovery pathways in liver transplantation is scarce, and lacks standardization. The highest level of evidence (level 1 or 2) was available for 13 out of 22 items. While the value of ERAS pathways has now been demonstrated in liver, colorectal and pancreas surgery showing benefit in morbidity, cost and medico-economic outcomes, there is a clear need to perform high-quality studies to confirm the benefit of ERAS pathways in liver transplantation. In conclusion, the proposed ERAS pathway for liver transplantation is based on the best available evidence, which still needs to be further explored.

To allow benchmarking and comparison across trials using the new proposed liver transplantation ERAS recommendations, there is a need for consensual and standardized outcomes in liver transplantation, which are currently lacking.<sup>25</sup> In this line, a standardized and consensual checklist criteria to assess readiness for hospital discharge (or functional recovery) after LT was recently proposed.<sup>45</sup> Moreover, as highlighted by Muller X. et al<sup>46</sup> in a multicentre analysis to define benchmarks in LT, 82% of patients developed at least 1

complication during 1-year follow-up. When the latter is taken into account, probably the weight of morbidity as an outcome in ERAS guidelines validation should be reconsidered. Lastly, as with all existing ERAS pathways, the assessment of adherence to the protocol (compliance) is of utmost importance, and the compliance with the new proposed liver transplantation ERAS protocol should be documented, as part of further trial to allow benchmarking.

ACCEPTED

## REFERENCES

1. Kehlet H. Fast-track colorectal surgery. *Lancet (London, England)*. 2008;371(9615):791–793. doi:10.1016/S0140-6736(08)60357-8
2. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery. *JAMA Surg*. 2017;152(3):292. doi:10.1001/jamasurg.2016.4952
3. Gustafsson UO, Scott MJ, Schwenk W, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. *Clin Nutr*. 2012;31(6):783–800. doi:10.1016/J.CLNU.2012.08.013
4. Melloul E, Lassen K, Roulin D, et al. Guidelines for perioperative care for pancreatoduodenectomy: enhanced recovery after surgery (ERAS) recommendations 2019. *World J Surg*. 2020;44(7):2056–2084. doi:10.1007/s00268-020-05462-w
5. Melloul E, Hübner M, Scott M, et al. Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations. *World J Surg*. 2016;40(10):2425–2440. doi:10.1007/s00268-016-3700-1
6. Lau CSM, Chamberlain RS. Enhanced recovery after surgery programs improve patient outcomes and recovery: a meta-analysis. *World J Surg*. 2017;41(4):899–913. doi:10.1007/s00268-016-3807-4
7. Brustia R, Slim K, Scatton O. Enhanced recovery after liver surgery. *J Visc Surg*. 2019;156(2):127–137. doi:10.1016/j.jviscsurg.2018.10.007
8. Hughes MJ, McNally S, Wigmore SJ. Enhanced recovery following liver surgery: a systematic review and meta-analysis. 2014;16(8):699–706. doi:10.1111/hpb.12245
9. Dienstag JL, Cosimi AB. Liver transplantation--a vision realized. *N Engl J Med*. 2012;367(16):1483–1485. doi:10.1056/NEJMp1210159
10. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. a report from the European Liver Transplant Registry



- (ELTR). *J Hepatol*. 2012;57(3):675–688. doi:10.1016/j.jhep.2012.04.015
11. Adam R, Delvart V, Karam V, et al. Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. *Am J Transplant*. 2015;15(2):395–406. doi:10.1111/ajt.13060
  12. Adam R, Karam V, Cailliez V, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. *Transpl Int*. 2018;31(12):1293–1317. doi:10.1111/tri.13358
  13. Rana A, Ackah RL, Webb GJ, et al. No gains in long-term survival after liver transplantation over the past three decades. *Ann Surg*. 2019;269(1):20–27. doi:10.1097/SLA.0000000000002650
  14. Montano-Loza AJ, Meza-Junco J, Prado CMM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2012;10(2):166–173. doi:10.1016/j.cgh.2011.08.028
  15. Mourad MM, Liossis C, Gunson BK, et al. Etiology and management of hepatic artery thrombosis after adult liver transplantation. *Liver Transplant*. 2014;20(6):713–723. doi:10.1002/lt.23874
  16. Axelrod DA, Lentine KL, Xiao H, et al. National assessment of early biliary complications following liver transplantation: Incidence and outcomes. *Liver Transplant*. 2014;20(4):446–456. doi:10.1002/lt.23829
  17. Zhang W, Fung J. Limitations of current liver transplant immunosuppressive regimens: renal considerations. *Hepatobiliary Pancreat Dis Int*. 2017;16(1):27–32.
  18. Daugaard TR, Pommergaard HC, Rostved AA, et al. Postoperative complications as a predictor for survival after liver transplantation – proposition of a prognostic score. *HPB*. 2018;20(9):815–822. doi:10.1016/j.hpb.2018.03.001
  19. Brustia R, Monsel A, Conti F, et al. Enhanced recovery in liver transplantation: a

- feasibility study. *World J Surg.* 2019;43(1):230–241. doi:10.1007/s00268-018-4747-y
20. Rao J-H, Zhang F, Lu H, et al. Effects of multimodal fast-track surgery on liver transplantation outcomes. *Hepatobiliary Pancreat Dis Int.* 2017;16(4):364–369. doi:10.1016/S1499-3872(17)60020-1
  21. Brindle M, Nelson G, Lobo DN, et al. Recommendations from the ERAS® Society for standards for the development of enhanced recovery after surgery guidelines. *BJS Open.* 2020;4(1):157–163. doi:10.1002/bjs5.50238
  22. Brouwers MC, Kerkvliet K, Spithoff K, AGREE Next Steps Consortium ANS. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. *BMJ.* 2016;352:i1152. doi:10.1136/bmj.i1152
  23. Abeles A, Kwasnicki RM, Darzi A. Enhanced recovery after surgery: Current research insights and future direction. *World J Gastrointest Surg.* 2017;9(2):37. doi:10.4240/WJGS.V9.I2.37
  24. Lassen K, Coolen MME, Slim K, et al. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. *Clin Nutr.* 2012;31(6):817–830. doi:10.1016/j.clnu.2012.08.011
  25. Brustia R, Dechartres A, Scatton O. A methodological review of clinical outcomes reported in liver transplantation trials. *HPB.* 2020;22(6):833–844. doi:10.1016/j.hpb.2019.12.010
  26. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5(1):210. doi:10.1186/s13643-016-0384-4
  27. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928. doi:10.1136/BMJ.D5928
  28. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized

- clinical trials: is blinding necessary? *Control Clin Trials* . 1996;17(1):1–12.
29. Guyatt GH, Oxman AD, Vist GE, et al. Rating quality of evidence and strength of recommendations : GRADE : an emerging consensus on rating quality of evidence and strength of recommendations. *Br Med J*. 2008;336:924.  
doi:10.1136/bmj.39489.470347.AD
  30. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700. doi:10.1136/bmj.b2700
  31. Booth A, Clarke M, Gherzi D, et al. An international registry of systematic-review protocols. *Lancet (London, England)*. 2011;377(9760):108–109. doi:10.1016/S0140-6736(10)60903-8
  32. Centre for Evidence-based Medicine. Oxford Centre for Evidence-based Medicine: Levels of Evidence (March 2009). Available from <https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>. Accessed September 5, 2019.
  33. Bischoff SC, Singer P, Koller M, et al. Standard operating procedures for ESPEN guidelines and consensus papers. *Clin Nutr*. 2015;34(6):1043–1051.  
doi:10.1016/j.clnu.2015.07.008
  34. Schmidt RC. Managing Delphi surveys using nonparametric statistical techniques. *Decis Sci*. 1997;28(3):763–774. doi:10.1111/j.1540-5915.1997.tb01330.x
  35. Hsu C-C. The Delphi Technique: Making Sense of Consensus - Practical Assessment, Research & Evaluation. 2007;12(10).
  36. Rowe G, Wright G. The Delphi technique as a forecasting tool: issues and analysis. *Int J Forecast*. 1999;15(4):353–375.
  37. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and

- their use in clinical guideline development. *Health Technol Assess*. 1998;2(3):1–88.
38. Donohoe H, Stelfox M, Tennant B. Advantages and limitations of the e-Delphi technique: implications for health education researchers. *Am J Health Educ*. 2012;43(1):38–46.
39. Pomery A, Schofield P, Xhilara M, et al. Pragmatic, consensus-based minimum standards and structured interview to guide the selection and development of cancer support group leaders: a protocol paper. *BMJ Open*. 2017;7(6):e014408. doi:10.1136/bmjopen-2016-014408
40. Blaschke S, O’Callaghan CC, Schofield P. Nature-based care opportunities and barriers in oncology contexts: a modified international e-Delphi survey. *BMJ Open*. 2017;7(10):e017456. doi:10.1136/bmjopen-2017-017456
41. Boukdedid R, Abdoul H, Loustau M, et al. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. *PLoS One*. 2011;6(6). doi:10.1371/JOURNAL.PONE.0020476
42. Reese PP, Yeh H, Thomasson AM, et al. Transplant center volume and outcomes after liver retransplantation. *Am J Transplant*. 2009;9(2):309–317. doi:10.1111/j.1600-6143.2008.02488.x
43. Bailey MD, Godfrey EL, Frankel WC, et al. A data-driven approach to defining the volume-outcome relationship in liver transplantation. Available at <https://atcmeetingabstracts.com/abstract/a-data-driven-approach-to-defining-the-volume-outcome-relationship-in-liver-transplantation/>. Accessed October 13, 2020.
44. Macomber CW, Shaw JJ, Santry H, et al. Centre volume and resource consumption in liver transplantation. *HPB*. 2012;14(8):554–559. doi:10.1111/j.1477-2574.2012.00503.x
45. Brustia R, Boleslawski E, Monsel A, et al. Definition and prospective assessment of

- functional recovery after liver transplantation: a new objective, consensus-based metric for safe discharge. *Liver Transplant*. 2020;26(10):1241–1253 doi:10.1002/lt.25841.
46. Muller X, Marcon F, Sapisochin G, et al. Defining benchmarks in liver transplantation: a multicenter outcome analysis determining best achievable results. *Ann Surg*. 2018;267(3):419–425. doi:10.1097/SLA.0000000000002477
  47. Volk ML, Roney M, Fagerlin A. Pilot test of a patient decision aid about liver transplant organ quality. *Liver Transplant*. 2014;20(7):850–855. doi:10.1002/lt.23882
  48. Op den Dries S, Annema C, Berg AP van den, et al. Shared decision making in transplantation: how patients see their role in the decision process of accepting a donor liver. *Liver Transpl*. 2014;20(9):1072–1080. doi:10.1002/lt.23921
  49. Brustia R, Savier E, Scatton O. Physical exercise in cirrhotic patients: Towards prehabilitation on waiting list for liver transplantation. A systematic review and meta-analysis. *Clin Res Hepatol Gastroenterol*. 2018;42(3):205–215. doi:10.1016/j.clinre.2017.09.005.
  50. Aamann L, Dam G, Rinnov AR, et al. Physical exercise for people with cirrhosis. *Cochrane Database Syst Rev*. 2018;12(12):CD012678. doi:10.1002/14651858.CD012678.pub2.
  51. Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. *Clin Nutr*. 2019;38(2):485–521. doi:10.1016/j.clnu.2018.12.022
  52. Tandon P, Raman M, Mourtzakis M, et al. A practical approach to nutritional screening and assessment in cirrhosis. *Hepatology*. 2017;65(3):1044–1057. doi:10.1002/hep.29003
  53. Grąt M, Wronka KM, Lewandowski Z, et al. Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. *Clin Nutr*. 2017;36(6):1530–1539. doi:10.1016/j.clnu.2017.04.021.

54. Plank LD, Mathur S, Gane EJ, et al. Perioperative immunonutrition in patients undergoing liver transplantation: A randomized double-blind trial. *Hepatology*. 2015;61(2):639–647. doi:10.1002/hep.27433
55. Lei Q, Wang X, Zheng H, et al. Peri-operative immunonutrition in patients undergoing liver transplantation: A meta-analysis of randomized controlled trials. *Asia Pac J Clin Nutr*. 2015;24(4):583–590. doi:10.6133/apjcn.2015.24.4.20
56. Smith MD, Mccall J, Plank L, et al. Preoperative carbohydrate treatment for enhancing recovery after elective surgery. *Cochrane Database Syst Rev*. 2014;8:CD009161. doi:10.1002/14651858.CD009161.pub2.
57. Berry PS, Rosenberger LH, Guidry CA, et al. Intraoperative versus extended antibiotic prophylaxis in liver transplant surgery: a randomized controlled pilot trial. *Liver Transplant*. 2019;25(7):1043–1053. doi:10.1002/lt.25486.
58. Gurusamy KS, Nagendran M, Davidson BR. Methods of preventing bacterial sepsis and wound complications after liver transplantation. *Cochrane Database Syst Rev*. 2014;4:CD006660. doi:10.1002/14651858.CD006660.pub3
59. Pratschke S, Rauch A, Albertsmeier M, et al. Temporary intraoperative porto-caval shunts in piggy-back liver transplantation reduce intraoperative blood loss and improve postoperative transaminases and renal function: a meta-analysis. *World J Surg*. 2016;40(12):2988–2998. doi:10.1007/s00268-016-3656-1
60. Nacif LS, Zanini LY, Sartori VF, et al. Intraoperative surgical portosystemic shunt in liver transplantation: systematic review and meta-analysis. *Ann Transplant*. 2018;23:721–732. doi:10.12659/AOT.911435
61. Lee JJM, Yoo YJ, Lee JJM, et al. Sevoflurane versus desflurane on the incidence of postreperfusion syndrome during living donor liver transplantation: A randomized controlled trial. *Transplantation*. 2016;100(3):600–606.

doi:10.1097/TP.0000000000000874

62. Milan ZB, Duncan B, Rewari V, et al. Subcostal transversus abdominis plane block for postoperative analgesia in liver transplant recipients. *Transplant Proc.* 2011;43(7):2687–2690. doi:10.1016/j.transproceed.2011.06.059
63. Tong K, Nolan W, O’Sullivan DM, et al. Implementation of a multimodal pain management order set reduces perioperative opioid use after liver transplantation. *Pharmacother J Hum Pharmacol Drug Ther.* 2019;39(10):975–982. doi:10.1002/phar.2322
64. Li J, Wang C, Jiang Y, et al. Immediate versus conventional postoperative tracheal extubation for enhanced recovery after liver transplantation IPTE versus CTE for enhanced recovery after liver transplantation. *Med (United States).* 2018;97(45). doi:10.1097/MD.00000000000013082
65. Skurzak S, Stratta C, Schellino MM, et al. Extubation score in the operating room after liver transplantation. *Acta Anaesthesiol Scand.* 2010;54(8):970–978. doi:10.1111/j.1399-6576.2010.02274.x
66. Bulatao IG, Heckman MG, Rawal B, et al. Avoiding stay in the intensive care unit after liver transplantation: A score to assign location of care. *Am J Transplant.* 2014;14(9):2088–2096. doi:10.1111/ajt.12796
67. Gurusamy KS, Naik P, Davidson BR. Routine drainage for orthotopic liver transplantation. *Cochrane Database Syst Rev.* 2011;6:CD008399. doi:10.1002/14651858.cd008399.pub2
68. Carrier FM, Chassé M, Wang HT, et al. Restrictive fluid management strategies and outcomes in liver transplantation: a systematic review. *Can J Anesth Can d’anesthésie.* 2020;67(1):109–127. doi:10.1007/s12630-019-01480-y.
69. Bezinover D, Dirkmann D, Findlay J, et al. Perioperative coagulation management in

- liver transplant recipients. *Transplantation*. 2018;102(4):578–592.  
doi:10.1097/TP.0000000000002092
70. Weinberg L, Huang A, Alban D, et al. Prevention of hypothermia in patients undergoing orthotopic liver transplantation using the humigard® open surgery humidification system: a prospective randomized pilot and feasibility clinical trial. *BMC Surg*. 2017;17(1):10. doi:10.1186/s12893-017-0208-z
71. Janicki PK, Stoica C, Chapman WC, et al. Water warming garment versus forced air warming system in prevention of intraoperative hypothermia during liver transplantation: a randomized controlled trial [ISRCTN32154832]. *BMC Anesthesiol*. 2002;2(1):7.
72. Langer G, Großmann K, Fleischer S, et al. Nutritional interventions for liver-transplanted patients. *Cochrane Database Syst Rev*. 2012;(8):CD007605.  
doi:10.1002/14651858.CD007605.PUB2
73. Kamo N, Kaido T, Hamaguchi Y, et al. Impact of enteral nutrition with an immunomodulating diet enriched with hydrolyzed whey peptide on infection after liver transplantation. *World J Surg*. 2018;42(11):3715–3725. doi:10.1007/s00268-018-4680-0
74. Maffei P, Wiramus S, Bensoussan L, et al. Intensive early rehabilitation in the intensive care unit for liver transplant recipients: a randomized controlled trial. *Arch Phys Med Rehabil*. 2017;98(8):1518–1525. doi:10.1016/j.apmr.2017.01.028
75. Schaller SJ, Anstey M, Blobner M, et al. Early, goal-directed mobilisation in the surgical intensive care unit: a randomised controlled trial. *Lancet*. 2016;388(10052):1377–1388. doi:10.1016/S0140-6736(16)31637-3
76. Park C, Hsu C, Neelakanta G, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation.



- Transplantation*. 2009;87(7):1031–1036. doi:10.1097/TP.0b013e31819cc3e6
77. Wallia A, Parikh ND, Molitch ME, et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. *Transplantation*. 2010;89(2):222–226. doi:10.1097/TP.0b013e3181c3c2ff
78. Wallia A, Parikh ND, O’Shea-Mahler E, et al. Glycemic control by a glucose management service and infection rates after liver transplantation. *Endocr Pract*. 2011;17(4):546–551. doi:10.4158/EP10343.OR
79. Wallia A, Schmidt K, Oakes DJ, et al. Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. *J Clin Endocrinol Metab*. 2017;102(2):451–459. doi:10.1210/jc.2016-3279
80. Bardet JD, Charpiat B, Bedouch P, et al. Illness representation and treatment beliefs in liver transplantation: An exploratory qualitative study. *Ann Pharm Fr*. 2014;72(5):375–387. doi:10.1016/j.pharma.2014.05.005
81. Asavakarn S, Sirivatanauksorn Y, Promraj R, et al. Systematic pharmaceutical educational approach to enhance drug adherence in liver transplant recipients. *Transplant Proc*. 2016;48(4):1202–1207. doi:10.1016/j.transproceed.2015.12.100
82. Ko D, Lee I, Muehrer RJ. Informational needs of liver transplant recipients during a two-year posttransplant period. *Chronic Illn*. 2016;12(1):29v40. doi:10.1177/1742395315601415

**TABLE 1** Characteristics of the selected studies.

**TABLE 2** Summary of ERAS recommendations for each item and the respective level of evidence.

**FIGURE 1** Flowchart of included studies

**FIGURE 2** Characteristics of the expert panelists (experience, specialty, and LT volume).

**FIGURE 3** Trend of consensus rating for each criterion across the e-Delphi rounds. The asterisks on the items 4 (antibiotic prophylaxis) and 13 (fluid and blood management) mean that an agreement was reached within the first round, but major rephrasing was proposed by the panel. The consensus rate was maintained above 80% for these 2 items during the second round.

Supplementary\_material\_study\_list <http://links.lww.com/TP/C225> . List and characteristics of included studies

**Table 1. Characteristics of the selected studies**

	<b>Overall (n=43)</b>
<b>Publication Year</b>	
2000	1 (2.3%)
2002	1 (2.3%)
2007	1 (2.3%)
2009	1 (2.3%)
2010	3 (7.0%)
2011	2 (4.7%)
2013	2 (4.7%)
2014	5 (11.6%)
2015	4 (9.3%)
2016	7 (16.3%)
2017	8 (18.6%)
2018	4 (9.3%)
2019	4 (9.3%)
<b>Location Corresponding Author</b>	
Africa	1 (2.3%)
Asia	8 (18.6%)
Australia	2 (4.7%)
Europe	16 (37.2%)
North America	13 (30.2%)
South America	3 (7.0%)
<b>Study Design</b>	
Cohort	17 (39.5%)
RCT	12 (27.9%)
Case-control	7 (16.3%)
Before-after	6 (14.0%)
Outcome research	1 (2.3%)
<b>If observational</b>	
Prospective	24 (55.8%)
Retrospective	19 (44.2%)
<b>If RCT</b>	
Unblinded	8 (18.6%)
Double blind	4 (9.3%)
Single blind	1 (2.3%)
<b>Single/multicenter</b>	
Single center	40 (93.0%)
Multicenter, National	2 (4.7%)
Multicenter, International	1 (2.3%)
<b>Total number of patients enrolled</b>	
Mean (SD)	227 (496)
Median [25 <sup>th</sup> , 75 <sup>th</sup> ]	105 [40, 171]
<b>Level of Evidence, Oxford</b>	
1	12 (27.9%)

2	15 (34.9%)
3	7 (16.3%)
4	9 (20.9%)
<b>Indication of LT (reported)</b>	
Yes	32 (74.4%)
No	11 (25.6%)
<b>Type of graft</b>	
Deceased donor	15 (34.9%)
LDLT	9 (20.9%)
Both	3 (7.0%)
Not detailed	16 (37.2%)
<b>Timing of intervention</b>	
Preoperative (including prehabilitation)	3 (7.0%)
Intraoperative or perioperative	24 (55.8%)
Early postoperative (up to discharge)	11 (25.6%)
Late postoperative or followup	5 (11.6%)
<b>Class of intervention</b>	
Medical treatment (including antibiotherapy)	13 (30.2%)
Anesthesiology	11 (25.6%)
Nutritional support	6 (14.0%)
Physical therapy	5 (11.6%)
Other	4 (9.3%)
Surgical technique	3 (7.0%)
Psychology education	1 (2.3%)
<b>Type of intervention</b>	
Non pharmacologic	23 (53.5%)
Pharmacologic	19 (44.2%)
Combined	1 (2.3%)
<b>Impact on Morbidity</b>	
Decreased	11 (25.6%)
No difference	13 (30.2%)
Unclear	2 (4.7%)
Increased	1 (2.3%)
<b>Impact on Mortality</b>	
No difference	16 (37.2%)
Decreased	1 (2.3%)
Unclear	1 (2.3%)
<b>Impact on Liver Graft Dysfunction</b>	
Decreased	5 (11.6%)
Increased	1 (2.3%)
No difference	17 (39.5%)
<b>Impact on Length of Stay</b>	
Decreased	5 (11.6%)
Increased	1 (2.3%)
No difference	17 (39.5%)
<b>JADAD score</b>	

-2	1 (2.0%)
-1	2 (4.0%)
0	1 (2.0%)
1	3 (6.0%)
2	2 (4.0%)
3	1 (2.0%)
5	2 (4.0%)
6	1 (2.0%)
<b>GRADE Level of Evidence</b>	
High	3 (6.0%)
Moderate	19 (38.0%)
Low	18 (36.0%)
Very Low	10 (20.0%)
<b>Selection bias</b>	
No	6 (14.0%)
Unclear	1 (2.3%)
Yes	5 (11.6%)
<b>Allocation concealment bias</b>	
No	6 (14.0%)
Unclear	4 (9.3%)
Yes	2 (4.7%)
<b>Performance bias</b>	
No	5 (11.6%)
Yes	7 (16.3%)
<b>Detection bias</b>	
No	4 (9.3%)
Yes	8 (18.6%)
<b>Attrition bias</b>	
No	6 (14.0%)
Unclear	3 (7.0%)
Yes	3 (7.0%)
RCT= randomized controlled trial, SD=standard deviation, LT=liver transplantation, LDLT=living donor liver transplantation,	

Table 2. ERAS Item	Summary	Evidence Level	Grade of recommendation
<b>1 PREOPERATIVE COUNSELING</b>	Patients on waiting list should receive dedicated, multidisciplinary educational counselling. <sup>47,48</sup>	Low	Strong
<b>2 PREHABILITATION</b>	<b>Adapted Physical therapy</b> There is no evidence yet of the benefit or harm of physical exercise in cirrhotic patients before liver transplantation. <sup>49,50</sup>	Low	Weak
	<b>Preoperative nutritional screening</b> Patients with cirrhosis should be screened for malnutrition, using a validated tool, and addressed to a multidisciplinary team for nutritional intervention. <sup>51,52</sup>	Moderate	Strong
	<b>Preoperative nutrition</b> cirrhotic patients malnourished or in the preoperative period should receive 30-35 Kcal x kg <sup>-1</sup> x d <sup>-1</sup> and a protein intake of 1.5 g x kg <sup>-1</sup> x d <sup>-1</sup> , through a standard nutrition regimen minimizing periods of starvation, with no need of protein restriction in case of HE. <sup>51</sup>	High	Strong
	<b>Probiotics</b> Some evidence supports the use of probiotics, prior to, or on the day of liver transplantation. The duration of the treatment and the number of strains included are variable across the studies. <sup>53,54</sup>	High	Weak
	<b>Preoperative immunonutrition</b> the available evidence is nonconclusive, and no recommendation can be given for systematic IN before LT. <sup>55</sup>	High	Weak
<b>3 PERIOPERATIVE FASTING AND CARBOHYDRATE LOADING</b>	<b>Preoperative fasting</b> Preoperative fasting does not need to exceed 6 h for solids and 2 h for liquids. Caution should be considered in case of risk factors for delayed gastric emptying (tense ascites, diabetes or autonomic dysfunction). <sup>5,51</sup>	Low	Strong
	<b>Carbohydrate loading</b> Carbohydrate loading may be recommended at patient admission for liver transplantation, at least 2 h before induction of anaesthesia. <sup>5,56</sup> Caution should be considered in case of risk factors for delayed gastric emptying (tense ascites, diabetes or autonomic dysfunction).	Low	Weak
<b>4 ANTIMICROBIAL PROPHYLAXIS</b>	It is recommended to administer antibiotic prophylaxis only during the intraoperative period. Extending the duration of prophylaxis does not provide any advantages. Systematic selective digestive decontamination is not recommended. <sup>57,58</sup>	Moderate	Strong

<b>5 ANTITHROMBOTIC PROPHYLAXIS</b>	<b>Antithrombotic prophylaxis</b> There is no evidence in favour or against thrombotic prophylaxis, but compressive stockings and intermittent pneumatic compression devices during LT may be recommended.	Very Low	Weak
	<b>Anticoagulation prophylaxis</b> There is insufficient evidence to provide any formal recommendation on antiaggregation or anticoagulation. When available, the viscoelastic coagulation monitoring may be used to guide the therapeutic decision.	Very Low	Weak
<b>6 ANESTHETIC PREMEDICATION</b>	Long-acting anxiolytic drugs should be avoided. Dose-adjusted, short-acting anxiolytics may be considered in selected patients.	Very Low	Weak
<b>7 INCISION</b>	The choice of incision is at the surgeon's discretion, depending on the graft and patient's morphology. Mercedes-type incision may probably be avoided due to higher risk of incisional hernia.	Low	Weak
<b>8 TEMPORARY PORTOCAVAL SHUNT</b>	The available evidence suggest that the use of temporary porto-caval surgical shunt may be beneficial in reducing the red blood cell transfusion requirement, length of stay, PNF and mortality rates. <sup>59,60</sup> Its use is however submitted to the surgeon and anaesthesiologist's decision during surgery.	Low	Weak
<b>9 SHORT ACTING ANESTHETIC PROTOCOL</b>	Short acting anesthetics can be considered in LT, and within anesthetic gases, little evidence suggest that sevoflurane may be preferred to desflurane. <sup>61</sup> Cerebral or nociception monitoring anesthetic titration may be critically used. Neuromuscular monitoring should guide the appropriate level of muscle relaxation and reversal.	Low	Strong
<b>10 PERIOPERATIVE ANALGESIA</b>	We recommend using multimodal and balanced analgesia to manage perioperative analgesia after LT. There is not enough published evidence to state in favor or against an opioid-sparing management: PCA-based morphine may be considered, with caution among patients at high risk for delirium. TAP block may be considered, while TEA cannot be recommended after LT. <sup>62,63</sup>	Low	Strong
<b>11 EARLY EXTUBATION</b>	Each patient undergoing LT should be screened for eligibility to early extubation (< 3-8h). <sup>64</sup> The eligibility should rely on published scores and on local policies and organization for postoperative monitoring. <sup>65,66</sup>	Low	Strong

<b>12 ABDOMINAL DRAINAGE</b>	There is insufficient evidence to recommend no routine drain policy in liver transplantation. <sup>67</sup> Whenever a drain is used, it may be advisable to remove as soon as possible. It can be considered to systematically drain the peritoneal cavity of patients affected by refractory ascites.	Low	Weak
<b>13 FLUID MANAGEMENT</b>	A restrictive fluid management strategy may carefully be considered during LT over a more liberal one. <sup>68</sup> Indirect evidence from other major surgery population suggest that a goal-directed fluid therapy may provide better outcomes than standard of care. TEE may be considered to target fluid therapy.	Low	Weak
	<b><i>Intraoperative blood product management</i></b> When available, Viscoelastic tests as Thromboelastography (TEG) or Rotational Thromboelastometry (ROTEM) might be used to drive the management of blood products and factor concentrates during LT. <sup>69</sup>	Low	Weak
<b>14 PERIOPERATIVE NORMOTHERMIA</b>	Perioperative normothermia should be maintained during liver transplantation. <sup>70,71</sup>	Low	Strong
<b>15 PROPHYLACTIC NASOGASTRIC PROBE</b>	Indirect evidence suggest that routine postoperative nasogastric probe after liver transplantation is not indicated. Nasogastric tubes placed during surgery should be removed before reversal of anaesthesia.	Low	Strong
<b>16 POSTOPERATIVE NAUSEA AND VOMITING</b>	Indirect evidence suggest the use of a multimodal approach to PONV, with 2 antiemetic drugs as prophylaxis (e.g. 5-HT3 antagonist and steroids).	Low	Strong
<b>17 EARLY ORAL NUTRITION</b>	Normal food oral intake and/or enteral nutrition (nasogastric tube or jejunostomy) should be started 12-24h after liver transplantation, according to patient's tolerance. Parenteral nutrition should be considered as the very last option, when the use of oral route (enteral feeding tubes or jejunostomy) is not possible. <sup>51</sup>	Very Low	Strong
	<b><i>Nutritional supplements</i></b> There is no clear evidence of the benefit of nutritional supplements after liver transplantation. <sup>72,73</sup>	Low	Weak
<b>18 EARLY MOBILISATION</b>	Early mobilization after LT should be encouraged with early-goal directed interventions, from the morning after LT until hospital discharge. <sup>75,76</sup> Physical rehabilitation may be continued after discharge.	Moderate	Strong



<b>19 GLYCEMIC CONTROL</b>	We recommend a protocolized approach to blood glucose management in LT patients targeting an upper blood glucose level $\leq 180$ mg/dL from the intraoperative period to the early postoperative period (first 24-48 hours postoperatively in the absence of complications and/or organ failure). <sup>77-80</sup>	Moderate	Strong
<b>20 POSTOPERATIVE ILEUS</b>	There are no acknowledged strategies to prevent postoperative ileus after LT.	Low	Weak
<b>21 POSTOPERATIVE EDUCATION</b>	Systematic educational programs after liver transplantation may increase patient awareness and knowledge on the immunosuppressive therapy and on physical changes after LT. Such multidisciplinary programs could include a clinical pharmacist, and should be continued over a long period after liver transplantation. <sup>80-82</sup>	Low	Strong
<b>22 AUDIT</b>	Systematic audit improves compliance and clinical outcome in healthcare practice. <sup>2,4,5</sup>	Moderate	Strong

---

LT=liver transplantation, Kcal=kilocalories, IN=immunonutrition, h=hours

---

Figure 1




Figure 2




Figure 3

